An empirical evaluation of the global deterioration scale for staging Alzheimer's disease

Carl Eisdorfer, Donna Cohen, Gregory J. Paveza, J. Wesson Ashford, Daniel J. Luchins, Philip B. Gorelick, Robert S. Hirschman, Sally A. Freels, Paul S. Levy, Todd P. Semla, Helen A. Shaw

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Objective: Although the Global Deterioration Scale has been widely used since its publication in 1982, its stages are based on implicit assumptions about the linearity, temporality, and interdependence of cognitive, functional, and behavioral impairment in Alzheimer's disease. The authors evaluated the validity of these assumptions and tested the hypothesis that psychopathology and functional impairment would occur in earlier stages than the Global Deterioration Scale predicts. Method: The analyses were based on data on 324 patients with Alzheimer's disease who were selected from a registry of such patients. Data analyses included 1) descriptive statistics on the frequency of psychiatric symptoms and difficulties with activities of daily living and 2) logistic regression, with symptoms and functional impairment as independent variables, to test for significant changes in patients' status between stages of the Global Deterioration Scale. Results: More than 50% of the patients at stage 2 displayed psychopathology, and 32% had two or more symptoms. The significant increase in psychiatric symptoms occurred between stages 3 and 4, not between stages 5 and 6 as predicted by the Global Deterioration Scale. Impairment in functional status was observed at all stages, and significant increases occurred between stages 3 and 4 as well as between stages 5 and 6. Conclusions: Psychiatric symptoms and functional impairment occur earlier than predicted by the Global Deterioration Scale, and the rate of change is also different from that specified in the scale. Separate scales to describe cognitive, clinical, and functional status may be the best way to describe the illness until better multidimensional instruments are developed.

Original languageEnglish
Pages (from-to)190-194
Number of pages5
JournalAmerican Journal of Psychiatry
Volume149
Issue number2
StatePublished - Dec 1 1992
Externally publishedYes

Fingerprint

Alzheimer Disease
Psychiatry
Psychopathology
Activities of Daily Living
Registries
Publications
Logistic Models

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Eisdorfer, C., Cohen, D., Paveza, G. J., Ashford, J. W., Luchins, D. J., Gorelick, P. B., ... Shaw, H. A. (1992). An empirical evaluation of the global deterioration scale for staging Alzheimer's disease. American Journal of Psychiatry, 149(2), 190-194.

An empirical evaluation of the global deterioration scale for staging Alzheimer's disease. / Eisdorfer, Carl; Cohen, Donna; Paveza, Gregory J.; Ashford, J. Wesson; Luchins, Daniel J.; Gorelick, Philip B.; Hirschman, Robert S.; Freels, Sally A.; Levy, Paul S.; Semla, Todd P.; Shaw, Helen A.

In: American Journal of Psychiatry, Vol. 149, No. 2, 01.12.1992, p. 190-194.

Research output: Contribution to journalArticle

Eisdorfer, C, Cohen, D, Paveza, GJ, Ashford, JW, Luchins, DJ, Gorelick, PB, Hirschman, RS, Freels, SA, Levy, PS, Semla, TP & Shaw, HA 1992, 'An empirical evaluation of the global deterioration scale for staging Alzheimer's disease', American Journal of Psychiatry, vol. 149, no. 2, pp. 190-194.
Eisdorfer C, Cohen D, Paveza GJ, Ashford JW, Luchins DJ, Gorelick PB et al. An empirical evaluation of the global deterioration scale for staging Alzheimer's disease. American Journal of Psychiatry. 1992 Dec 1;149(2):190-194.
Eisdorfer, Carl ; Cohen, Donna ; Paveza, Gregory J. ; Ashford, J. Wesson ; Luchins, Daniel J. ; Gorelick, Philip B. ; Hirschman, Robert S. ; Freels, Sally A. ; Levy, Paul S. ; Semla, Todd P. ; Shaw, Helen A. / An empirical evaluation of the global deterioration scale for staging Alzheimer's disease. In: American Journal of Psychiatry. 1992 ; Vol. 149, No. 2. pp. 190-194.
@article{b4cf25afe15f4f239f1df8538496150e,
title = "An empirical evaluation of the global deterioration scale for staging Alzheimer's disease",
abstract = "Objective: Although the Global Deterioration Scale has been widely used since its publication in 1982, its stages are based on implicit assumptions about the linearity, temporality, and interdependence of cognitive, functional, and behavioral impairment in Alzheimer's disease. The authors evaluated the validity of these assumptions and tested the hypothesis that psychopathology and functional impairment would occur in earlier stages than the Global Deterioration Scale predicts. Method: The analyses were based on data on 324 patients with Alzheimer's disease who were selected from a registry of such patients. Data analyses included 1) descriptive statistics on the frequency of psychiatric symptoms and difficulties with activities of daily living and 2) logistic regression, with symptoms and functional impairment as independent variables, to test for significant changes in patients' status between stages of the Global Deterioration Scale. Results: More than 50{\%} of the patients at stage 2 displayed psychopathology, and 32{\%} had two or more symptoms. The significant increase in psychiatric symptoms occurred between stages 3 and 4, not between stages 5 and 6 as predicted by the Global Deterioration Scale. Impairment in functional status was observed at all stages, and significant increases occurred between stages 3 and 4 as well as between stages 5 and 6. Conclusions: Psychiatric symptoms and functional impairment occur earlier than predicted by the Global Deterioration Scale, and the rate of change is also different from that specified in the scale. Separate scales to describe cognitive, clinical, and functional status may be the best way to describe the illness until better multidimensional instruments are developed.",
author = "Carl Eisdorfer and Donna Cohen and Paveza, {Gregory J.} and Ashford, {J. Wesson} and Luchins, {Daniel J.} and Gorelick, {Philip B.} and Hirschman, {Robert S.} and Freels, {Sally A.} and Levy, {Paul S.} and Semla, {Todd P.} and Shaw, {Helen A.}",
year = "1992",
month = "12",
day = "1",
language = "English",
volume = "149",
pages = "190--194",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "2",

}

TY - JOUR

T1 - An empirical evaluation of the global deterioration scale for staging Alzheimer's disease

AU - Eisdorfer, Carl

AU - Cohen, Donna

AU - Paveza, Gregory J.

AU - Ashford, J. Wesson

AU - Luchins, Daniel J.

AU - Gorelick, Philip B.

AU - Hirschman, Robert S.

AU - Freels, Sally A.

AU - Levy, Paul S.

AU - Semla, Todd P.

AU - Shaw, Helen A.

PY - 1992/12/1

Y1 - 1992/12/1

N2 - Objective: Although the Global Deterioration Scale has been widely used since its publication in 1982, its stages are based on implicit assumptions about the linearity, temporality, and interdependence of cognitive, functional, and behavioral impairment in Alzheimer's disease. The authors evaluated the validity of these assumptions and tested the hypothesis that psychopathology and functional impairment would occur in earlier stages than the Global Deterioration Scale predicts. Method: The analyses were based on data on 324 patients with Alzheimer's disease who were selected from a registry of such patients. Data analyses included 1) descriptive statistics on the frequency of psychiatric symptoms and difficulties with activities of daily living and 2) logistic regression, with symptoms and functional impairment as independent variables, to test for significant changes in patients' status between stages of the Global Deterioration Scale. Results: More than 50% of the patients at stage 2 displayed psychopathology, and 32% had two or more symptoms. The significant increase in psychiatric symptoms occurred between stages 3 and 4, not between stages 5 and 6 as predicted by the Global Deterioration Scale. Impairment in functional status was observed at all stages, and significant increases occurred between stages 3 and 4 as well as between stages 5 and 6. Conclusions: Psychiatric symptoms and functional impairment occur earlier than predicted by the Global Deterioration Scale, and the rate of change is also different from that specified in the scale. Separate scales to describe cognitive, clinical, and functional status may be the best way to describe the illness until better multidimensional instruments are developed.

AB - Objective: Although the Global Deterioration Scale has been widely used since its publication in 1982, its stages are based on implicit assumptions about the linearity, temporality, and interdependence of cognitive, functional, and behavioral impairment in Alzheimer's disease. The authors evaluated the validity of these assumptions and tested the hypothesis that psychopathology and functional impairment would occur in earlier stages than the Global Deterioration Scale predicts. Method: The analyses were based on data on 324 patients with Alzheimer's disease who were selected from a registry of such patients. Data analyses included 1) descriptive statistics on the frequency of psychiatric symptoms and difficulties with activities of daily living and 2) logistic regression, with symptoms and functional impairment as independent variables, to test for significant changes in patients' status between stages of the Global Deterioration Scale. Results: More than 50% of the patients at stage 2 displayed psychopathology, and 32% had two or more symptoms. The significant increase in psychiatric symptoms occurred between stages 3 and 4, not between stages 5 and 6 as predicted by the Global Deterioration Scale. Impairment in functional status was observed at all stages, and significant increases occurred between stages 3 and 4 as well as between stages 5 and 6. Conclusions: Psychiatric symptoms and functional impairment occur earlier than predicted by the Global Deterioration Scale, and the rate of change is also different from that specified in the scale. Separate scales to describe cognitive, clinical, and functional status may be the best way to describe the illness until better multidimensional instruments are developed.

UR - http://www.scopus.com/inward/record.url?scp=0026528882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026528882&partnerID=8YFLogxK

M3 - Article

VL - 149

SP - 190

EP - 194

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 2

ER -